Arcus Biosciences Net Income vs. Current Valuation
| RCUS Stock | USD 16.41 0.75 4.37% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -93 M | Current Value -92 M | Quarterly Volatility 64.4 M |
For Arcus Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arcus Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arcus Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arcus Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arcus Biosciences over time as well as its relative position and ranking within its peers.
Arcus |
Arcus Biosciences' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.05) | Revenue Per Share 3.058 | Quarterly Revenue Growth 0.5 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arcus Biosciences Current Valuation vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Arcus Biosciences's current stock value. Our valuation model uses many indicators to compare Arcus Biosciences value to that of its competitors to determine the firm's financial worth. Arcus Biosciences is rated below average in net income category among its peers. It is rated below average in current valuation category among its peers . At this time, Arcus Biosciences' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcus Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Arcus Current Valuation vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Arcus Biosciences |
| = | (307 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Arcus Biosciences |
| = | 612.55 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Arcus Current Valuation vs Competition
Arcus Biosciences is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 28.77 Billion. Arcus Biosciences holds roughly 612.55 Million in current valuation claiming about 2.13% of equities under Health Care industry.
Arcus Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Arcus Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arcus Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Arcus Biosciences' change in net profit over the period of time. It can combine multiple indicators of Arcus Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -6.3 M | -6 M | |
| Net Interest Income | 39 M | 41 M | |
| Interest Income | 41 M | 43 M | |
| Operating Income | -340 M | -323 M | |
| Net Loss | -307 M | -291.6 M | |
| Income Before Tax | -301 M | -285.9 M | |
| Total Other Income Expense Net | 39 M | 41 M | |
| Net Loss | -240.3 M | -228.3 M | |
| Net Loss | -307 M | -291.6 M | |
| Income Tax Expense | 6 M | 6.3 M | |
| Non Operating Income Net Other | 357.3 K | 339.4 K | |
| Change To Netincome | 87.4 M | 91.8 M | |
| Net Loss | (4.15) | (3.94) | |
| Income Quality | 1.00 | 1.05 | |
| Net Income Per E B T | 1.02 | 0.78 |
Arcus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Arcus Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arcus Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arcus Biosciences' important profitability drivers and their relationship over time.
Use Arcus Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcus Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcus Biosciences will appreciate offsetting losses from the drop in the long position's value.Arcus Biosciences Pair Trading
Arcus Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Arcus Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcus Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcus Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcus Biosciences to buy it.
The correlation of Arcus Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcus Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcus Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcus Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Arcus Biosciences position
In addition to having Arcus Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.